コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 single nucleotide incorporation catalyzed by HIV reverse transcriptase.
2 centrations and temperatures and apply it to HIV reverse transcriptase.
3 strate or zalcitabine, an inhibitor used for HIV reverse transcriptase.
4 effectively depletes the dNTP substrates of HIV reverse transcriptase.
5 han the corresponding reaction observed with HIV reverse transcriptase.
6 toxicity of anti-retroviral drugs targeting HIV reverse transcriptase.
7 ymerase, T7 DNA-dependent RNA polymerase and HIV reverse transcriptase.
8 anism of RNase H and drug design targeted to HIV reverse transcriptase.
9 IV activity, and they also failed to inhibit HIV reverse transcriptase.
10 ncy virus, type I (HIV) RNase H, a domain of HIV reverse transcriptase.
11 recognized by the ribonuclease H function of HIV reverse transcriptase.
12 merase-alpha and polymerase-beta, as well as HIV reverse transcriptase.
13 a significant and dose-dependent increase of HIV reverse transcriptase activity in human blood monocy
16 ynucleosides, which are potent inhibitors of HIV reverse transcriptase and other viral DNA polymerase
20 delity of DENV polymerase is comparable with HIV reverse transcriptase and the poliovirus polymerase.
21 , apply it to family A and B polymerases and HIV reverse transcriptase, and discuss factors that may
22 hybrid decreases the rate of both human and HIV reverse transcriptase-associated RNase H-mediated cl
23 of published crystal structures showed that HIV reverse transcriptase binds only two metal ions prio
25 tor of HBV and human immunodeficiency virus (HIV) reverse transcriptases, but substitutions of isoleu
30 SARS-CoV-2 RNA-dependent RNA polymerase and HIV reverse transcriptase, enabling live-cell RNA imagin
31 of the class I MHC-HLA2 complex bound to the HIV reverse transcriptase epitope, ILKEPVHGV, and in the
32 were determined by analyzing 155,462 single HIV reverse transcriptase gene (RT) and 6,985 vif sequen
34 udies here show that at the same shift motif HIV reverse transcriptase generates -1 and +1 indels wit
36 tion of functional TNA aptamers that bind to HIV reverse transcriptase (HIV RT) with K(D)'s of ~0.4-4
42 ninyl phenyl ester prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV; 9-[(
43 istant virus, next generation non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) with impro
44 everal lavendamycins were found to be potent HIV reverse transcriptase inhibitors with very low toxic
45 e chain in RB69 DNA polymerase (Arg-482) and HIV reverse transcriptase (Lys-65) were previously obser
46 dition, the optical control mechanism of the HIV reverse transcriptase-mediated RT process was elucid
49 atrix peptide (a model recall antigen) or an HIV reverse transcriptase peptide (a model novel antigen
51 ted HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, integrase, and core
53 of toxicity to human cells, incorporation by HIV reverse transcriptase, resistance to repair when inc
55 clovir in HIV-infected cells is validated as HIV reverse transcriptase (RT) by the emergence of the R
57 V naturally contain high uracil content, and HIV reverse transcriptase (RT) does not distinguish betw
58 mation systems, we have examined variants of HIV reverse transcriptase (RT) for their ability to synt
59 e analogues leads to a novel class of potent HIV reverse transcriptase (RT) inhibitors, alpha-carboxy
61 s (NNRTIs) with activity against variants of HIV reverse transcriptase (RT) is crucial for overcoming
67 rimer for synthesis of the (+) DNA strand by HIV reverse transcriptase (RT), and which is not digeste
68 n(2+), and Zn(2+) have been shown to inhibit HIV reverse transcriptase (RT), presumably by competitiv
73 tion of human immunodeficiency virus type 1 (HIV) reverse transcriptase (RT) and protease (PT) sequen
74 riation in the human immunodeficiency virus (HIV) reverse transcriptase (RT) and protease enzymes, th
75 riation in the human immunodeficiency virus (HIV) reverse transcriptase (RT) and protease enzymes, th
76 d drug-related human immunodeficiency virus (HIV) reverse transcriptase (RT) and protease sequence va
77 ctions between human immunodeficiency virus (HIV) reverse transcriptase (RT) and structures mimicking
78 Inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) are widely used in the t
80 suggested that human immunodeficiency virus (HIV) reverse transcriptase (RT) binds to the 5' end of R
81 he fidelity of human immunodeficiency virus (HIV) reverse transcriptase (RT) has been a subject of in
83 , derived from human immunodeficiency virus (HIV)-reverse transcriptase (RT) residues 309-317, are mo
85 identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kina
87 work ideas to build a detailed model for the HIV reverse transcriptase that is consistent with existi
88 readily incorporated into a DNA template by HIV reverse transcriptase to act as a DNA chain terminat
89 predictable drug resistance mutation in the HIV reverse transcriptase to label and track cells infec
93 cell) extracts, and they were substrates for HIV-reverse transcriptase without being substrates for D